PharmiWeb Today Story
LONDON, UK, 30 November 2022 – Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). The MHRA decision applies to England, Scotland, and Wales (Great Britain). Voclosporin is the first and only oral CNI licensed in Great Britain (GB) specifically for the treatment of active LN in adult patients.
“The MHRA’s authorisation of Lupkynis represents a significant development for lupus nephritis patients in Great Britain, offering voclosporin as a new combination treatment option for eligible patients.” said Ryan Gynne, Managing Director of Otsuka Pharmaceuticals UK Ltd.
LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease, that can cause irreversible kidney damage4. UK data from 2012 showed that around 60,000 people were living with SLE and around 3,000* people were diagnosed with SLE each year5. Around 40% to 60% of people with SLE develop lupus nephritis6,7.
Voclosporin is a calcineurin-inhibitor immunosuppressant that inhibits calcineurin in a dose-dependent manner up to a maximum dose of 1.0mg/kg. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens8.
▼ This medicine is subject to additional monitoring in relati…Read More...
10 Time Management Tips for Recruiters
13 Top Tips for an Amazing Job Interview
Pharmaceutical Manufacturing & Packaging Congress…
28-Jun-2021 - 29-Jun-2021
6th CAR-TCR Summit
30-Aug-2021 - 02-Sep-2021
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021
Bioprocessing and the future of food
06-Jul-2022 - 07-Jul-2022
PM Society: Measuring Patient Engagement: Opening…
12-Oct-2022 - 12-Oct-2022
AI in Healthcare Summit Boston 2022
13-Oct-2022 - 14-Oct-2022
Energous Corporation Grants Inducement Restricted…
$400 Million Biological Safety Cabinet (Class I, C…
Medical Tubing Global Market Report 2022: Trend Sh…
Everest Clinical Research Announces the Acquisitio…
Global Bacteriophage Therapy Market Report 2022: L…
Global Nutrigenomics Market Report 2022 to 2035: I…